Basaglar KwikPen

Basaglar is a prescription-only long-acting insulin used for blood sugar level management in people with diabetes. Basaglar is prescribed for adults with type 1 or type 2 diabetes mellitus. It is also prescribed for children aged 6 years and older with type 1 diabetes. In people with type 1 diabetes, it is used along with a short-acting insulin taken at mealtimes. It works gradually after injection to provide steady blood sugar control for up to 24 hours (duration may vary between individuals).

Basaglar KwikPen is FDA-approved for:

• Type 1 diabetes (adults and children)
• Type 2 diabetes (adults only)

What Are the Benefits of Basaglar KwikPen Insulin?

• It’s easy to use and convenient to carry.
• A clear dose window helps avoid dosing mistakes.
• Approved for children aged 6 years & older with type 1 diabetes.

If you are prescribed a prefilled Basaglar KwikPen for diabetes, follow these administration guidelines:

Preparing the Pen

• This KwikPen should be used only after thoroughly washing your hands with soap and water.
• Always use a new needle with each Basaglar KwikPen injection to prevent infections and blocked needles.
• Pull the pen cap straight off the pen without removing the pen label.
• Clean the rubber seal of the Basaglar injection with an alcohol swab.
• Check the insulin in the pen and ensure it is clear and colorless, with no particles or clumps.
• Select a new needle and remove the paper tab from the outer needle shield before attaching it to the pen.
• Attach the capped needle by pushing it straight on and turning until secure.
• Remove the outer needle shield and keep it for later disposal, then remove and discard the inner needle shield.
• Prime the pen before every injection to remove air and ensure accurate dosing.
• Turn the dose knob on the pen to 2 units for priming.

Setting the Basaglar Dose

• Hold the prefilled Basaglar KwikPen with the needle pointing upward. After that, gently tap the cartridge holder to move air bubbles to the top.
• Select your prescribed dose on the pen by turning the dose knob until the correct number appears in the dose window.
• If your dose exceeds 80 units, give more than one injection using the pen as directed by your healthcare provider.

Injecting the Insulin

• Choose an injection site on the stomach, buttocks, upper legs, or upper arms when using the pen.
• Clean the site of the injection with an alcohol swab. Allow it to dry completely.
• Insert the pen’s needle into the skin and push the dose knob.
• Hold the dose knob in place for 5 seconds before removing the needle to make sure the full dose is delivered.
• Remove the needle from the skin and check that “0” appears in the dose window of the pen.
• If “0” does not appear, do not redial the dose and follow medical guidance for missed or partial doses.
• Apply gentle pressure if bleeding occurs after a Basaglar KwikPen injection, but do not rub the area.
• Carefully recap the needle using the outer needle shield after using the pen.
• Unscrew and dispose of the capped needle safely after each injection.
• You should never store the KwikPen with a needle attached, as this may cause leakage or allow air to enter.
• You can replace the Pen Cap by aligning it with the dose indicator, then push it straight on.

Important Notes:

• Rotate injection sites when using the Basaglar KwikPen to reduce lipodystrophy or localized cutaneous amyloidosis.
• You should avoid injecting insulin into tender, scarred, bruised, thickened, or damaged areas.

• You can put used needles straight into an FDA‑cleared sharps container after each injection.
• Never leave needles loose or throw them directly in household trash.
• If you don’t have an FDA‑approved container, use a strong household plastic container that is:
• Heavy and leakproof
• Puncture‑resistant
• Can close tightly and stay upright
• Clearly labeled as “hazardous.”
• When the sharps container is nearly full, follow your local disposal rules (these may differ by area).
• Do not put a full sharps container in regular trash unless local rules allow it.
• After removing the needle safely, dispose of the empty pen in accordance with local regulations.

Basaglar contains insulin glargine, a long‑acting insulin. Once injected under the skin, it slowly releases into the bloodstream over about 24 hours. The insulin helps move sugar (glucose) from the blood into muscle and fat cells, where it can be used for energy. At the same time, it tells the liver to stop making extra sugar. This dual action lowers blood sugar, prevents spikes, and provides a steady background insulin level. In addition, it reduces the breakdown of fat and protein while supporting protein synthesis in the body. The result is smoother, more stable blood sugar control with just one daily injection.

If you have missed a Basaglar KwikPen dose, use it as soon as you remember. If it’s already close to your next scheduled Basaglar KwikPen dose, skip the missed one. After that, you can continue with your regular routine. Do not take extra insulin to make up for the missed dose, as this can cause your blood sugar to drop too low.

If you have taken a Basaglar KwikPen overdose, your blood sugar may fall dangerously low. Overdosing on Basaglar KwikPen causes issues like low blood sugar symptoms, including shakiness, sweating, dizziness, confusion, or blurred vision. You should treat mild symptoms quickly with fast‑acting sugar, such as juice or glucose tablets. If symptoms are serious, such as fainting or seizures, contact the poison control center or your healthcare provider immediately.

When you consider the Basaglar KwikPen dose for diabetes, follow this table:

• Do not use the Basaglar KwikPen for diabetes after the expiration date or more than 28 days after first use.
• Always check the pen label to confirm you are using the correct type of insulin. This is especially true if you use more than one insulin.
• Avoid drinking alcohol while using Basaglar KwikPen. Alcohol can increase the risk of dangerously low blood sugar.
• Basaglar may be used during pregnancy when clinically indicated. Insulin requirements may change during pregnancy and postpartum.
• Basaglar KwikPen is generally considered safe to use while breastfeeding when prescribed by a doctor.
• The usage of this pen can cause low blood sugar levels that can affect alertness and reaction time. Avoid driving if you feel unwell or dizzy.
• Use this medication with caution if you have kidney problems. Basaglar KwikPen dose adjustments may be needed, and regular blood sugar monitoring is important.
• You should use this medication with caution if you have liver problems. Your doctor may need to adjust the dose based on your condition.

Storage Guidelines for Unopened Basaglar KwikPen:

• Store in the refrigerator at 2°C-8°C (36°F-46°F).
• Do not freeze. If frozen, discard the pen.

Storage Guidelines for Opened (in-use) Basaglar KwikPen:

• Store this pen at room temperature (up to 30°C or 86°F).
• Do not refrigerate after first use.
• Must be used within 28 days of opening.

General Basaglar KwikPen Storage Guidelines:

• Keep pens away from direct heat and sunlight.
• Do not store Basaglar KwikPen solution for injection if it is cloudy, colored, or contains particles.
• Always keep the pen cap on to protect it from light.

Basaglar KwikPen Storage Tips while Traveling:

• Carry unopened pens in a cooler bag with ice packs (avoid direct contact with ice).
• For opened pens, simply store them at room temperature, but avoid hot environments (like inside a car).

Basaglar (insulin glargine) interacts with 406 medications and has 3 disease-related interactions. Among these drug interactions, 16 are classified as major, 362 as moderate, and 28 as minor. Some of them are listed below:

• Major Interactions with Basaglar (Insulin Glargine)
  • Gemifloxacin
  • Ofloxacin
  • Capivasertib
  • Sparfloxacin
  • Cinoxacin
  • Levofloxacin
  • Nalidixic acid
  • Gatifloxacin
  • Lomefloxacin
  • Ciprofloxacin
• Minor Interactions with Basaglar (Insulin Glargine)
  • Diltiazem
  • Prednisolone ophthalmic
  • Rimexolone ophthalmic
  • Fluorometholone ophthalmic
  • Potassium chloride
• Some Moderate Interactions with Basaglar (Insulin Glargine)
  • Metformin
  • Risperidone
  • Hydrocortisone topical
  • Fenofibric acid
  • Somatropin
  • Acebutolol
  • Tranylcypromine
  • Levothyroxine
  • Clobetasol topical
  • Ginseng
  • Sulfamethoxazole
  • Quetiapine
• Basaglar Disease Interactions
  • Renal/liver disease
  • Hypokalemia
  • Hypoglycemia

• Lantus (insulin glargine)
• Toujeo (insulin glargine, U-300)
• Levemir (insulin detemir)
• Tresiba (insulin degludec)

In the U.S., the cost of Basaglar KwikPen for diabetes is a major concern for those who cannot purchase it. When insurance coverage is limited or unavailable, many patients feel forced to delay refills or stretch doses. This puts their diabetes management strategy in real jeopardy. At Polar Bear Meds, we understand these concerns and work to make diabetes care more accessible.

By sourcing the Basaglar KwikPen solution for injection from licensed Canadian pharmacies, we help patients save up to 80% compared to many U.S. pharmacy prices. New customers can also use the Basaglar KwikPen coupon code “WELCOMEPB10” to get 10% additional discount, with no insurance required and no hidden fees. Plus, you can expect delivery of Basaglar KwikPen within 3-5 days via our Xpress Post for added convenience.

• https://pi.lilly.com/us/basaglar-KwikPen-us-ifu.pdf
• https://www.drugs.com/basaglar.html
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae